questionText: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 December 2023 to Question 4318 on Prostate Cancer: Drugs, when does she expect NHS England to complete their consideration of a clinical policy proposal for abiraterone as a treatment option for patients newly diagnosed with high risk, non-metastatic, hormone-sensitive prostate cancer.
answerText: There are no plans for a comparative assessment to be made. Health is a devolved matter and decisions on access to medicines in Scotland and Wales are a matter for the devolved administrations.NHS England sent a policy proposition to stakeholders on 29 No...
heading: Prostate Cancer: Drugs